52 results
8-K
EX-10.1
PCSA
Processa Pharmaceuticals Inc
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether … or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties
8-K
EX-4.3
PCSA
Processa Pharmaceuticals Inc
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
for their reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.
f
8-K
EX-4.1
PCSA
Processa Pharmaceuticals Inc
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.
f) Restrictions. The Holder acknowledges
8-K
EX-4.2
PCSA
Processa Pharmaceuticals Inc
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
be reimbursed by the other party for their reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution
8-K
EX-10.2
7g6 6skrg
24 Mar 22
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.1
l99elryf6a bowen
24 Mar 22
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-1.1
au4uu
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.1
x8w4cxlr 1vh7n
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
8-K
EX-10.1
dpctss2iuh3jegy
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-10.2
jold 7ircqf98k
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-1.1
rbed9b5n75mdz oh9nk
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
424B4
8qa7 8ru9ipnyn
5 Oct 20
Prospectus supplement with pricing info
4:16pm